Enterprise Value
79.51M
Cash
268.7M
Avg Qtr Burn
-71.4M
Short % of Float
27.36%
Insider Ownership
3.09%
Institutional Own.
-
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ZORYVE® (ARQ-151) topical roflumilast cream (PDE4 Inhibitor) Details Psoriasis, Skin disease/disorder | Approved Quarterly sales | |
ZORYVE® (ARQ-151) topical roflumilast cream (PDE4 Inhibitor) Details Psoriasis, Skin disease/disorder, Chronic obstructive pulmonary disease, Pulmonary hypertension | Approved Quarterly sales | |
ARQ-151 topical roflumilast cream (PDE4 Inihibitor) Details Atopic dermatitis | PDUFA Approval decision | |
Roflumilast foam 0.3% Details Skin disease/disorder, Seborrheic dermatitis Big Mover™ Suspected Mover™ Susp. Mover™ | PDUFA Approval decision | |
ARQ-151 topical roflumilast cream (PDE4 Inihibitor) Details Atopic dermatitis | sNDA Submission | |
ARQ-154 topical roflumilast foam (PDE4 inhibitor) Details Psoriasis, Skin disease/disorder | sNDA Submission | |
ARQ-255 topical ivarmacitinib (JAK1 inhibitor) Details Skin disease/disorder, Alopecia areata | Phase 1b Data readout | |
ARQ-252 (JAK1i) Details Skin disease/disorder, Eczema | Failed Discontinued | |
ARQ-252 (JAKi) Details Vitiligo | Failed Discontinued |